La aparición de los stents liberadores de fármacos ha supuesto uno de los grandes hitos en el intervencionismo percutáneo de la cardiopatía isquémica y ha logrado en muy poco tiempo una aceptación unánime en todo el mundo y un crecimiento exponencial en el número de unidades implantadas.
Después de varios años de un entusiasmo excesivo en los que se ha constatado, sin ninguna duda, un beneficio claro sobre el talón de Aquiles de la angioplastia coronaria, como es el problema de la reestenosis, empiezan a surgir ciertas dudas acerca de la seguridad a largo plazo de estos dispositivos, fundamentadas en la aparición de casos tardíos de trombosis intra-stent, en ocasiones muy alejados en el tiempo, con consecuencias adversas para los pacientes.
Palabras clave
Stent recubierto
Trombosis tardía
Reendotelización
Doble antiagregación plaquetaria
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
A.R. Grüntzig, A. Senning, W.E. Siegenthaler.
Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.
N Engl J Med, (1979), 301 pp. 61-68
[2.]
P.W. Serruys, P. de Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heydrick, For the Benestent Study group, et al.
A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.
N Engl J Med, (1994), 331 pp. 489-495
[3.]
D.L. Fischman, M.B. Leon, D.S. Baim, R.A. Schatz, M.P. Savage, I. Penn, For the Stent Restenosis Study Investigators, et al.
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.
N Engl J Med, (1994), 331 pp. 496-550
[4.]
H.C. Lowe, S.N. Oesterle, L.M. Khachigian.
Coronary in-stent restenosis: current status and future strategies.
J Am Coll Cardiol, (2002), 39 pp. 183-193
[5.]
J.E. Sousa, M.A. Costa, A.C. Abizaid, B.J. Rensing, A.S. Abizaid, L.F. Tanajura, et al.
Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.
Circulation, (2001), 104 pp. 2007-2011
[6.]
M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, E. Ban Hayashi, M. Perin, et al.
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
N Engl J Med, (2002), 346 pp. 1773-1780
[7.]
I. Moussa, C. Di Mario, B. Reimers, T. Akiyama, J. Tobis, A. Colombo.
Subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.
J Am Coll Cardiol, (1997), 29 pp. 6-12
[8.]
D.E. Cutlip, D.S. Baim, K.K. Ho, J. Popma, A. Lansky, D. Cohen, et al.
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Circulation, (2001), 103 pp. 1967-1971
[9.]
J.L. Orford, R. Lennon, S. Melby, P. Fasseas, M.R. Bell, C.H. Rihal, et al.
Frequency and Correlates of coronary stent thrombosis in the modern era. Analysis of a single centre registry.
Am Coll Cardiol, (2002), 40 pp. 1567-1572
[10.]
M.A. Costa, M. Sabate, W.J. Van der Giessen, P. Kay, P. Cervinha, J.M. Ligthart, et al.
Late coronary occlusion after intracoronary brachytherapy.
Circulation, (1999), 100 pp. 789-792
[11.]
J. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, For the SIRIUS investigators, et al.
Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery.
N Engl J Med, (2003), 349 pp. 1315-1323
[12.]
J. Fajadet, M.C. Morice, C. Bode, P. Barragan, P.W. Serruys, W. Wijns, et al.
Maintenance of long term clinical benefit with sirolimus eluting stents. Three year results of the RAVEL trial.
Circulation, (2005), 111 pp. 1040-1044
[13.]
G. Weisz, M.B. Leon, D.R. Holmes, D.J. Kereiakes, M.R. Clark, B.M. Cohen, et al.
Two year outcomes after sirolimus stent implantation. Results from the sirolimus eluting stent in de novo native coronary lesions (SIRIUS) trial.
J Am Coll Cardiol, (2006), 47 pp. 1350-1355
[14.]
G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughneesy, J.T. Mann, TAXUS-IV Investigators, et al.
A polymer-based, paclitaxel-eluting stent in patient with coronary artery disease.
N Engl J Med, (2004), 350 pp. 221-231
[15.]
P.A. Lemos, P.W. Serruys, R.W. Van Domburg, F. Saia, C.A. Arampatzis, A. Hoye, et al.
Unrestricted utilization of sirolimus eluting stents compared with conventional bare metal stent implantation in the real world: the Rapamycin Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.
Circulation, (2004), 109 pp. 190-195
[16.]
G.W. Stone, S.G. Ellis, L. Cannon, J.T. Mann, J.D. Greemberg, D. Spriggs, et al.
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial for the TAXUS V investigators.
JAMA, (2005), 294 pp. 1215-1223
[17.]
M.C. Morice, A. Colombo, B. Meier, P.W. Serruys, T. Corrado, J. Guagliumi, et al.
Sirolimus vs. paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
JAMA, (2006), 295 pp. 895-904
[18.]
A.T. Ong, P.W. Serruys, J. Aoki, A. Hoye, C.A. Van Mieghen, G.A. Rodriguez-Granillo, et al.
The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
J Am Coll Cardiol, (2005), 45 pp. 1135-1141
[19.]
J.M. De la Torre Hernández, F. Sainz Laso, M. Llano Cardenal, M. Ruiz-Lera, L. Rodríguez, V. Burgos, et al.
Seguimiento clínico a 2 años de 200 pacientes tratados con stent liberador de rapamicina en lesiones de alto riesgo de reestenosis.
Rev Esp Cardiol, (2006), 59 pp. 225-231
[20.]
J.M. De la Torre, F. Sainz Laso, C. Ruisanchez, J. Zueco, A. Figueroa, T. Colman.
Tratamiento de lesiones con alto riesgo de reestenosis. Estudio comparativo en 300 pacientes del stent liberador de rapamicina, el stent con polímero liberador de paclitaxel y el stent convencional.
Rev Esp Cardiol, (2005), 58 pp. 262-269
[21.]
C.H. Lee, H.C. Tan, H.Y. Ong, S.G. Teo, Y.T. Lim.
Late Thrombotic occlusion of paclitaxel eluting stent more than one year after stent implantation.
Heart, (2004), 90 pp. 1482-1484
[22.]
E. McFadden, E. Satbile, E. Regar, E. Cheneau, A.T. Ong, T. Kinnaird, et al.
Late thrombosis in drug-eluting stents after discontinuation of antiplatelet therapy.
Lancet, (2004), 364 pp. 1519-1521
[23.]
S.H. Wilson, P. Fasseas, J.L. Orford, R.J. Lennon, T. Horlocker, N. Charnoff, et al.
Clinical Outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.
J Am Coll Cardiol, (2003), 42 pp. 234-240
[24.]
A.T. Ong, A. Hoye, J. Aoki, C.A. Van Mieghem, G.A. Rodriguez Granillo, E.R. Sonnesnschein, et al.
Thirty-day incidence an six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.
J Am Coll Cardiol, (2005), 45 pp. 947-953
[25.]
A.T. Ong, E. McFadden, E. Regar, P.P. De Jaegere, R. Van Domburg, P.W. Serruys.
Late angiographic Stent Thrombosis (LAST) Events With Drug-eluting Stents.
J Am Coll Cardiol, (2005), 45 pp. 2088-2092
[26.]
I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, G. Stankovic, et al.
Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents.
JAMA, (2005), 293 pp. 2126-2130
[27.]
A.B. Bavry, D.J. Kumbhani, T.J. Helton, D.L. Bhatt.
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis.
J Am Coll Cardiol, (2005), 45 pp. 941-946
[28.]
R. Moreno, C. Fernández, R. Hernández, F. Alfonso, D. Angiolillo, M. Sabaté, et al.
Drug eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies.
J Am Coll Cardiol, (2005), 45 pp. 954-959
[29.]
D.J. Kereiakes, H. Wang, J.J. Popma, R.E. Kuntz, D.J. Donohoe, J. Schofer, et al.
Periprocedural and Late consequences of overlapping Cypher Sirolimus-Eluting stents. Pooled analysis of five clinical trials.
J Am Coll Cardiol, (2006), 48 pp. 21-31
[30.]
E. Schampaert, J.W. Moses, J. Schofer, M. Schluter, A.H. Gerslick, E.A. Cohen, et al.
Sirolimus-eluting stents at two years: A pooled analysis of SIRIUS, E-SIRIUS and C-SIRIUS with emphasis on late revascularizations and stent thromboses.
Am J Cardiol, (2006), 98 pp. 36-41
[31.]
P.K. Kuchulakanti, W.W. Chu, R. Torguson, P. Ohlman, S. Woon Rha, L.C. Clavijo, et al.
Correlates and long term outcomes of angiografically proven stent thrombosis with sirolimus and paclitaxel eluting stents.
Circulation, (2006), 113 pp. 1108-1113
[32.]
S. Windecker, A. Remondino, F.R. Eberli, P. Juni, L. Raber, P. Wenaweser, et al.
Sirolimus eluting stent and paclitaxel eluting stents for coronary revascularization.
N Engl J Med, (2005), 353 pp. 653-662
[33.]
C. Kaiser, H.P. Brunner-La Rocca, P. Buser, P. Rickenbacher, P. Hunziker, R. Jeger, et al.
Long–term cost-effectiveness of drug-eluting stents versus bare-metal stents in a real world setting: 18 months results of the BASKET trial.
Eur Heart J, (2006), pp. 829
[34.]
C. Kaiser, H.P. Brunner-La Rocca, P. Buser, P.O. Bonetti, S. Osswald, A. Linka, et al.
Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised.
Lancet, (2005), 366 pp. 921-929
[35.]
N. Kipshide, D. Dangas, M. Tsapenko, J. Moses, M.B. Leon, M. Kutryck, et al.
Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions.
J Am Coll Cardiol, (2004), 44 pp. 733-739
[36.]
M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Ladich, et al.
Pathology of drug-eluting stents in Humans. Delayed Healing and late Thrombotic risk.
J Am Coll Cardiol, (2006), 48 pp. 193-202
[37.]
R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, T. Motta, et al.
Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?.
Circulation, (2004), 109 pp. 701-705
[38.]
J. Kotani, M. Awata, S. Nanto, M. Uematsu, F. Oshima, H. Minamiguchi, et al.
Incomplete neointimal coverage of sirolimus-eluting stents.
J Am Coll Cardiol, (2006), 47 pp. 2108-2111
[39.]
T.A. Nguyen, J.G. Diodati, C. Pharand.
Resistance to clopidogrel: a review of the evidence.
J Am Coll Cardiol, (2005), 45 pp. 1157-1164
[40.]
P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, E.J. Topol.
Aprospective blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
J Am Coll Cardiol, (2003), 41 pp. 961-965
[41.]
P. Wenaveser, J. Dorffler-Melly, K. Imboden, S. Windecker, M. Togni, B. Meier, et al.
Stent thrombosis is associated with an impaired response to antiplatelet therapy.
J Am Coll Cardiol, (2005), 45 pp. 1748-1752
[42.]
D.J. Angiolillo, A. Fernández-Ortiz, E. Bernardo, C. Ramírez, M. Sabate, E. Jimenez-Quevedo, et al.
Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Am J Cardiol, (2006), 97 pp. 38-43
[43.]
E. Cheneau, L. Leborgne, G.S. Mintz, J. Kotani, A.D. Pichard, L.F. Satler, et al.
Predictors of subacute stent thrombosis. Results of a systematic intravascular ultrasound study.
Circulation, (2003), 108 pp. 43-47
[44.]
K. Fujii, S.G. Carlier, G.S. Mintz, Y. Yang, I. Moussa, G. Weisz, et al.
Stent Under-expansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation.
J Am Coll Cardiol, (2005), 45 pp. 995-998
Copyright ©
2007. Sociedad Española de Cardiología